Zimbabwe has turned down a significant American healthcare agreement worth $367m (272 million pounds) spanning five years due to Washington's insistence on confidential biological samples.
This rejection became public after a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official representative later explained that the United States was seeking health data for research and commercial purposes but refused to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further dialogue to secure a deal acceptable to all parties so the nation's critical HIV programme can proceed.
Wider Background
Zimbabwe's decision follows a similar situation in Kenya, where a high court suspended a similar deal with the US after concerns were raised about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral deals to boost openness and accountability.
Based on reports, 16 nations in Africa have to date agreed to similar health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the resulting innovations would be accessible to our citizens if a future health crisis arise."
National Interest and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were disrupting frameworks already established through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to manage potential pandemics.
"This mechanism is designed to guarantee that when a nation contributes its information, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how subsequent co-operation could be designed in a manner that respects the sovereignty and interests of both nations."
Health Experts Response
Medical experts expressed it recognised the official position, but recommended that talks must proceed given that a large portion of the country's HIV programmes depended on external financing.
"If technical issues exist, such as those involving information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it added.
This impasse emphasises the complex tensions between accepting vital international aid and protecting a country's data in an ever more data-driven world.